News | August 27, 2008

The CYPHER Sirolimus-Eluting Stent Outperforms the Taxus in People with Diabetes in New Data

August 28, 2008 – In patients with diabetes, the CYPHER Sirolimus-eluting coronary stent outperformed the Taxus stent with significantly lower rates of in-segment restenosis, target lesion revascularization and major adverse events at nine months, according to clinical data appearing recently in the Journal of the American College of Cardiology.

In this multi-center randomized clinical trial, the six month rate of in-segment restenosis was more than five times lower for the CYPHER stent compared to the Taxus stent (4 percent vs. 20.8 percent respectively). Most important for patients and physicians, key clinical outcomes measures were about four times lower for the CYPHER stent at nine-months, clinically driven TLR for the CYPHER stent was 1.5 percent compared to 6 percent for the Taxus stent, while the composite clinical endpoint of MACE was 2 percent for the CYPHER stent compared to 8 percent for the Taxus.

“These data provide interventional cardiologists with valuable new information about the use of drug-eluting stents in patients with diabetes, whose coronary artery disease presents such therapeutic challenges,” said Seong-Wook Park, M.D., Ph.D., FACC, and principal investigator of this trial. Dr. Park is from the Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Cordis has no financial relationship with Dr. Park.

“The significant reduction in restenosis associated with the CYPHER stent, which translated to better outcomes for patients in terms of TLR and overall MACE, is impressive. It also is encouraging to note the data in this study on the safety of the CYPHER stent in this difficult-to-treat patient population,” Dr. Park continued.

There was no difference between the two drug-eluting stents in the rates of death or myocardial infarction (heart attack). The rate of death was 0 percent for the CYPHER vs. 0.5 percent for the Taxus. The incidence of heart attack between the two groups was 0.5 percent.

The study included 400 patients divided evenly between the CYPHER Stent and the Taxus Stent (200 each) from five academic medical centers in Korea between May 2005 and March 2006. All patients had clinically defined diabetes. This study was supported by the Cardiovascular Research Foundation (Korea) and a grant from the Korean Ministry of Health and Welfare.

The CYPHER Stent does not have an approved indication for use in patients with diabetes in the U.S.

For more information: www.cypherstent.com, www.cordis.com, www.acc.org

Related Content

Abbott has pulled the Absorb Bioresorbable scaffold stent off the market.

The biggest cardiac technology story in September was Abbott pulled the Absorb Bioresorbable scaffold stent off the market because poor sales.

Feature | October 02, 2017
October 2, 2017 — Here is the list of the most popular articles and videos on the Diagnostic and Interventional Cardi
Biotronik Studies Demonstrate Efficacy of Minimizing Metal Burden in SFA Therapy
News | Stents Bare Metal| September 22, 2017
Physicians demonstrated that reducing metal burden in superficial femoral artery (SFA) therapy could effectively reduce...
Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Biotronik's Orsiro Drug-Eluting Stent Outperforms Xience in BIOFLOW-V Trial
News | Stents Drug Eluting| September 01, 2017
September 1, 2017 — Biotronik recently announced data from the BIOFLOW-V randomized trial comparing Orsiro and Xience
Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
FDA Approves Six-Month Primary Endpoint for Tack Endovascular System in Below the Knee Disease
News | Stents Peripheral| July 14, 2017
Intact Vascular Inc. announced the U.S. Food and Drug Administration (FDA) approved an Investigational Device Exemption...
Onyx DES 2.0 mm stent meets primary endpoints in small vessels
News | June 12, 2017
June 12, 2017 – The Medtronic Resolute Onyx Drug-Eluting Stent (DES) met its primary endpoint of target lesion failur
Overlay Init